Genmab — December 2016
-
-
der står ikke rigtigt noget i den MW med FS. kun flg: Årets vigtigste begivenhed herhjemme
"Daratumumabs (Genmabs Darzalex, red.) lancering – det produkt vil være et stort tema i mange år."
-
-
Aktien puster ud efter et år med masser af gode nyheder. Gamle penge i aktien søger nye græsgange. Nye penge suges ind i vakummet. Det tager lidt fornuftig tid at danne base før videre opstigning. Alt er som det skal være.
-
About the pan-Canadian Oncology Drug Review (pCODR)
Once Health Canada has approved a cancer drug for use in Canada, the
country's provinces and territories must decide if the drug will be eligible for public reimbursement. The CADTH pan-Canadian Oncology Drug Review (pCODR) plays an important role in their decision-making processes. -
-
Myeloma Canada submits that pERC failed to fully comprehend the gravity of this stage of disease in
patients. At this stage, patients have run out of options for treatment and are close to death. In
particular, the statement “there is a low probability that daratumumab would be cost-effective in this
population compared to other treatments” is at best conjectural and at worst insensitive. -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind